Dr. Drutz has an extensive background in the pharmaceutical and biotechnology industries, having been VP Biological Sciences and VP Clinical Research at SmithKline & French Laboratories (PA); VP Clinical Development at Daiichi Pharmaceutical Corporation (NJ); and President & CEO of Inspire Pharmaceuticals in RTP, NC (now public ISPH:NASDAQ). His clinical development experience includes ofloxacin otic (Floxin�), levofloxacin (Levoquin�), irinotecan (Camptosar�) and a variety of other drugs that have not yet reached registration. Dr. Drutz is currently a General Partner with Pacific Rim Ventures Co., Ltd., an international venture capital firm with extensive investments in late-stage therapeutics companies; Chairman of Tranzyme, Inc. (RTP, NC); and a Director of MethylGene Inc. (Montreal: MYG: TSX). Dr. Drutz holds an M.D. degree from the University of Louisville.